Medical Affairs Reputations: Type 2 Diabetes Mellitus (EU5)
What are the leading T2DM medical affairs teams get right, and what the trailing teams get wrong?
Medical affairs teams for several leading T2DM treatments in the EU5 seem to be ticking all the boxes in terms of interaction quality. Notwithstanding this, the diabetologists and primary care physicians we surveyed gave mixed views in terms of performance and satisfaction ratings; while some teams standout, others need to up their game. This report reveals how your team measures up, so you can learn from the successes, avoid the failures and build better relationships with physicians.
Learn what your team gets right, and where it’s going wrong in Medical Affairs Reputations: Type 2 Diabetes Mellitus (EU5).
Comparing 7 major melanoma treatments from Novo Nordisk, Boehringer Ingelheim, Sanofi, Merck & Co., Johnson & Johnson, Eli Lilly, and AstraZeneca, this report reveals:
Find out what more doctors want from your medical affairs team including:
Top Takeaways
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 12 medical affairs teams—answering important questions like:
What do physicians need?
We surveyed 150 diabetologists and primary care physicians from the EU5 (France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world.
All respondents:
We conducted the survey between July 3rd and July 12th, 2017.
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Medical affairs teams for several leading T2DM treatments in the EU5 seem to be ticking all the boxes in terms of interaction quality. Notwithstanding this, the diabetologists and primary care physicians we surveyed gave mixed views in terms of performance and satisfaction ratings; while some teams standout, others need to up their game. This report reveals how your team measures up, so you can learn from the successes, avoid the failures and build better relationships with physicians.
Learn what your team gets right, and where it’s going wrong in Medical Affairs Reputations: Type 2 Diabetes Mellitus (EU5).
Comparing 7 major melanoma treatments from Novo Nordisk, Boehringer Ingelheim, Sanofi, Merck & Co., Johnson & Johnson, Eli Lilly, and AstraZeneca, this report reveals:
Find out what more doctors want from your medical affairs team including:
- How physicians rate your team overall, and on 12 key medical affairs services.
- Which medical affairs services are most important, and what you can do to improve them.
- How, and how often doctors want to meet with your team.
Top Takeaways
- Almost the right stuff: The team that earns the highest overall quality score also gets the highest performance and satisfaction scores for most medical affairs services.
- Meanwhile, at the bottom of the pack: While the team that earns the lowest overall score in terms of interaction quality, some physicians are happy with its performance for some medical affairs services.
- Physicians are hungry for information: They identified 3 ways teams can improve information provision, and highlighted at least 1 specific type of information they want more of.
- All teams fail to hit the mark on one key service: Physicians are unhappy with the performance of all medical affairs teams on this attribute. Is it important for your brand? Find out which one.
- Every team has at least one area for improvement: Every brand’s medical affairs team falls short on one or more key medical affairs service, with some teams failing on three.
- Old fashioned contact methods the best: Despite digital communication platforms becoming more embedded, physicians favour face to face meetings over other forms of communication.
- Farxiga (dapagliflozin; AstraZeneca)
- Humalog (insulin lispro; Eli Lilly)
- Invokana (canagliflozin; Johnson & Johnson)
- Januvia (sitagliptin; Merck & Co.)
- Jardiance (empagliflozin; Eli Lilly/Boehringer Ingelheim)
- NovoLog (insulin aspart; Novo Nordisk)
- Toujeo (insulin glargine; Sanofi)
- Tradjenta (linagliptin; Eli Lilly/Boehringer Ingelheim)
- Tresiba (insulin degludec; Novo Nordisk)
- Trulicity (dulaglutide; Eli Lilly)
- Victoza (liraglutide; Novo Nordisk)
- Xultophy (insulin degludec/liraglutide; Novo Nordisk)
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 12 medical affairs teams—answering important questions like:
What do physicians need?
- How, and how often are they using your medical affairs team?
- What services do they consider most important?
- How often should you contact them? What channels are best?
- How memorable are your team’s interactions with doctors?
- How do doctors rank your team for performance and satisfaction in 12 key areas?
- How does your team compare to the competition—in each area, and overall?
- Are you delivering the services that are most important to doctors?
- Where do you need to improve?
- How can your team enhance its services?
We surveyed 150 diabetologists and primary care physicians from the EU5 (France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world.
All respondents:
- Have been practicing for between 3 and 35 years
- See at least 5 patients with melanoma in a typical month
- Devote at least 50% of their time to direct patient care
- Have interacted with at least one listed product’s medical affairs team in the past 6 months.
We conducted the survey between July 3rd and July 12th, 2017.
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
1. OBJECTIVES, SURVEY METHODOLOGY AND SAMPLING, PRODUCTS INCLUDED IN THE SURVEY, EXECUTIVE SUMMARY
2. CURRENT STATUS OF INTERACTIONS WITH DIFFERENT MEDICAL AFFAIRS TEAMS
2.1 Interactions in the past 6 months with Medical Affairs teams for each product
2.2 Current frequency of interactions with medical affair teams for each product
3. COMPETITIVE EVALUATION OF MEDICAL AFFAIRS TEAMS PERFORMANCE ON VARIOUS ATTRIBUTES
3.1 Evaluation of overall quality of interactions with Medical Affairs teams for each product
3.2 Attribute importance of Medical Affairs teams roles to physicians’ practice
3.3 EdgeMap analysis – Competitive evaluation on Medical Affairs teams performance on attributes
3.4 Competitive evaluation of physicians satisfaction of interaction with Medical Affairs teams
3.5 Need-Gap analysis by product
4. PREFERRED INTERACTION MEDIA, FREQUENCY, AND SUGGESTIONS FOR IMPROVEMENT
4.1 Preferred interaction media and frequency, and suggestions for improvement
5. APPENDIX
2. CURRENT STATUS OF INTERACTIONS WITH DIFFERENT MEDICAL AFFAIRS TEAMS
2.1 Interactions in the past 6 months with Medical Affairs teams for each product
2.2 Current frequency of interactions with medical affair teams for each product
3. COMPETITIVE EVALUATION OF MEDICAL AFFAIRS TEAMS PERFORMANCE ON VARIOUS ATTRIBUTES
3.1 Evaluation of overall quality of interactions with Medical Affairs teams for each product
3.2 Attribute importance of Medical Affairs teams roles to physicians’ practice
3.3 EdgeMap analysis – Competitive evaluation on Medical Affairs teams performance on attributes
3.4 Competitive evaluation of physicians satisfaction of interaction with Medical Affairs teams
3.5 Need-Gap analysis by product
4. PREFERRED INTERACTION MEDIA, FREQUENCY, AND SUGGESTIONS FOR IMPROVEMENT
4.1 Preferred interaction media and frequency, and suggestions for improvement
5. APPENDIX
